Viatris Inc vs Zoom Video Communications, Inc. — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Zoom Video Communications, Inc. trades at $96.83 (market cap $28.14B). The key difference: Zoom Video Communications, Inc. is the larger of the two by market cap, and Viatris Inc pays a 2.89% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals.
| VTRS | ZM | |
|---|---|---|
Market Cap | $19.09B | $28.14B |
Sector | Health | Technology |
52-Week High | $17.86 | $111.88 |
52-Week Low | $9.49 | $72.72 |
Enterprise Value | $31.21B | $20.95B |
Dividend Yield | 2.89% | — |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Zoom Communications (ZM) trades at $96.44, down 4.83% amid mixed signals. The stock shows bearish technical indicators with support at $95 and resistance at $99, while fundamentals reveal strong profitability with 77.3% gross margins and 65.19% net income margin. Recent Q2 earnings beat expectations with 4.9% revenue growth to $1.28B, but soft Q3 guidance triggered the selloff. Analyst consensus remains cautiously optimistic with a $119.63 price target despite near-term headwinds.
The outlook balances strong cash flow generation against growth deceleration concerns. Investment opportunity lies in ZM's enterprise revenue acceleration (7.8% growth) and attractive valuation (P/E 8.95), while risks include competitive pressure and execution on AI initiatives. The Anthropic IPO catalyst and new board appointment provide potential upside if growth reaccelerates.
Trailing returns across standard periods
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →